 | Up a level |
Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A. and Duarte, R. (2017). Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant., 52. S. S61 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Jagasia, M., Beohou, E., van der Werf, S., Niederwieser, D., Dreger, P., Meijer, E., Chevallier, P., Sengeloev, H., Blaise, D., Petersen, E., Cornelissen, J. J., Ehninger, G., Gribben, J., Caballero, D., Beguin, Y., Hallek, M., Jindra, P., Fanin, R., Delage, J., Maertens, J., Gedde-Dahl, T., Montoto, S., Kroger, N., Greinix, H. and Duarte, R. (2017). Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses. Bone Marrow Transplant., 52. S. S83 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365